| Name | Title | Contact Details |
|---|
The RNS® System is an award-winning technology developed and manufactured in Silicon Valley that has been recognized for its innovation. Similar to a pacemaker that monitors and responds to heart rhythms, the RNS System is the world`s first and only medical device that can monitor and respond to brain activity. NeuroPace was founded to design, develop, manufacture and market implantable devices for the treatment of neurological disorders with responsive stimulation. The company`s initial focus is the treatment of epilepsy, a debilitating neurological disorder affecting approximately 1% of the population worldwide.In addition to treating epilepsy, responsive neurostimulation holds the promise of treating several other disabling medical disorders that impact the quality of life for millions of patients around the world.
Medivia is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Able Ambulance is a Somerville, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.
Xena Health is a Hartford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.